Skip to main content
Top
Published in: Current Neurology and Neuroscience Reports 10/2017

01-10-2017 | Neuroimaging (N Pavese, Section Editor)

Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson’s Disease: Implication for Treatment

Authors: Stephane Thobois, Stephane Prange, Véronique Sgambato-Faure, Léon Tremblay, Emmanuel Broussolle

Published in: Current Neurology and Neuroscience Reports | Issue 10/2017

Login to get access

Abstract

Apathy, depression, and anxiety are among the most important non-motor signs of Parkinson’s disease (PD). This may be encountered at early stages of illness and represent a major source of burden. Understanding their pathophysiology is a major prerequisite for efficient therapeutic strategies. Anatomical and metabolic imaging studies have enabled a breakthrough by demonstrating that widespread abnormalities within the limbic circuits notably the orbitofrontal and anterior cingulate cortices, amygdala, thalamus, and ventral striatum are involved in the pathophysiology of depression, anxiety, and apathy in PD. Functional imaging has further shown that mesolimbic dopaminergic but also serotonergic lesions play a major role in the mechanisms of these three neuropsychiatric manifestations, which has direct therapeutic implications.
Literature
1.
go back to reference Castrioto A, Thobois S, Carnicella S, Maillet A, Krack P. Emotional manifestations of PD: neurobiological basis. Mov Disord. 2016;31(8):1103–13.CrossRefPubMed Castrioto A, Thobois S, Carnicella S, Maillet A, Krack P. Emotional manifestations of PD: neurobiological basis. Mov Disord. 2016;31(8):1103–13.CrossRefPubMed
2.
go back to reference Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord. 2015;30:121–7.CrossRefPubMed Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord. 2015;30:121–7.CrossRefPubMed
4.
go back to reference Matsui H, Nishinaka K, Oda M, Niikawa H, Komatsu K, Kubori T, et al. Depression in Parkinson’s disease. Diffusion tensor imaging study. J Neurol. 2007;254:1170–3.CrossRefPubMed Matsui H, Nishinaka K, Oda M, Niikawa H, Komatsu K, Kubori T, et al. Depression in Parkinson’s disease. Diffusion tensor imaging study. J Neurol. 2007;254:1170–3.CrossRefPubMed
5.
go back to reference Feldmann A, Illes Z, Kosztolanyi P, Illes E, Mike A, Kover F, et al. Morphometric changes of gray matter in Parkinson’s disease with depression: a voxel-based morphometry study. Mov Disord. 2008;23:42–6.CrossRefPubMed Feldmann A, Illes Z, Kosztolanyi P, Illes E, Mike A, Kover F, et al. Morphometric changes of gray matter in Parkinson’s disease with depression: a voxel-based morphometry study. Mov Disord. 2008;23:42–6.CrossRefPubMed
6.
go back to reference Kostic VS, Agosta F, Petrovic I, Galantucci S, Spica V, Jecmenica-Lukic M, et al. Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology. 2010;75:857–63.CrossRefPubMed Kostic VS, Agosta F, Petrovic I, Galantucci S, Spica V, Jecmenica-Lukic M, et al. Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology. 2010;75:857–63.CrossRefPubMed
7.
go back to reference • Skidmore FM, Yang M, Baxter L, von Deneen K, Collingwood J, He G, et al. Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease. NeuroImage. 2013;81:484–95. Resting state fMRI study illustrating the complexicity and differences of brain activity changes responsible for apathy and depression in PD. CrossRefPubMed • Skidmore FM, Yang M, Baxter L, von Deneen K, Collingwood J, He G, et al. Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease. NeuroImage. 2013;81:484–95. Resting state fMRI study illustrating the complexicity and differences of brain activity changes responsible for apathy and depression in PD. CrossRefPubMed
8.
go back to reference Surdhar I, Gee M, Bouchard T, Coupland N, Malykhin N, Camicioli R. Intact limbic-prefrontal connections and reduced amygdala volumes in Parkinson’s disease with mild depressive symptoms. Parkinsonism Relat Disord. 2012;18:809–13.CrossRefPubMed Surdhar I, Gee M, Bouchard T, Coupland N, Malykhin N, Camicioli R. Intact limbic-prefrontal connections and reduced amygdala volumes in Parkinson’s disease with mild depressive symptoms. Parkinsonism Relat Disord. 2012;18:809–13.CrossRefPubMed
9.
go back to reference van Mierlo TJ, Chung C, Foncke EM, Berendse HW, van den Heuvel OA. Depressive symptoms in Parkinson’s disease are related to decreased hippocampus and amygdala volume. Mov Disord. 2015;30:245–52.CrossRefPubMed van Mierlo TJ, Chung C, Foncke EM, Berendse HW, van den Heuvel OA. Depressive symptoms in Parkinson’s disease are related to decreased hippocampus and amygdala volume. Mov Disord. 2015;30:245–52.CrossRefPubMed
10.
go back to reference • Vriend C, Boedhoe PS, Rutten S, Berendse HW, van der Werf YD, van den Heuvel OA. A smaller amygdala is associated with anxiety in Parkinson’s disease: a combined FreeSurfer-VBM study. J Neurol Neurosurg Psychiatry. 2016;87(5):493–500. Recent MRI study underlying the role of amygdala in neuropsychiatric symptoms in PD. CrossRefPubMed • Vriend C, Boedhoe PS, Rutten S, Berendse HW, van der Werf YD, van den Heuvel OA. A smaller amygdala is associated with anxiety in Parkinson’s disease: a combined FreeSurfer-VBM study. J Neurol Neurosurg Psychiatry. 2016;87(5):493–500. Recent MRI study underlying the role of amygdala in neuropsychiatric symptoms in PD. CrossRefPubMed
11.
go back to reference • Huang C, Ravdin LD, Nirenberg MJ, Piboolnurak P, Severt L, Maniscalco JS, et al. Neuroimaging markers of motor and nonmotor features of Parkinson’s disease: an 18f fluorodeoxyglucose positron emission computed tomography study. Dement Geriatr Cogn Disord. 2013;35:183–96. FDG PET study highlighting the widespread metabolic disorders observed in relation to neuropsychiatric manifestations in PD. CrossRefPubMed • Huang C, Ravdin LD, Nirenberg MJ, Piboolnurak P, Severt L, Maniscalco JS, et al. Neuroimaging markers of motor and nonmotor features of Parkinson’s disease: an 18f fluorodeoxyglucose positron emission computed tomography study. Dement Geriatr Cogn Disord. 2013;35:183–96. FDG PET study highlighting the widespread metabolic disorders observed in relation to neuropsychiatric manifestations in PD. CrossRefPubMed
12.
go back to reference Huang P, Xuan M, Gu Q, Yu X, Xu X, Luo W, et al. Abnormal amygdala function in Parkinson’s disease patients and its relationship to depression. J Affect Disord. 2015;183:263–268.58.CrossRefPubMed Huang P, Xuan M, Gu Q, Yu X, Xu X, Luo W, et al. Abnormal amygdala function in Parkinson’s disease patients and its relationship to depression. J Affect Disord. 2015;183:263–268.58.CrossRefPubMed
13.
go back to reference Hu X, Song X, Yuan Y, Li E, Liu J, Liu W, et al. Abnormal functional connectivity of the amygdala is associated with depression in Parkinson’s disease. Mov Disord. 2015;30:238–44.CrossRefPubMed Hu X, Song X, Yuan Y, Li E, Liu J, Liu W, et al. Abnormal functional connectivity of the amygdala is associated with depression in Parkinson’s disease. Mov Disord. 2015;30:238–44.CrossRefPubMed
14.
go back to reference O'Callaghan C, Shine JM, Lewis SJ, Hornberger M. Neuropsychiatric symptoms in Parkinson’s disease: fronto-striatal atrophy contributions. Parkinsonism Relat Disord. 2014;20:867–72.CrossRefPubMed O'Callaghan C, Shine JM, Lewis SJ, Hornberger M. Neuropsychiatric symptoms in Parkinson’s disease: fronto-striatal atrophy contributions. Parkinsonism Relat Disord. 2014;20:867–72.CrossRefPubMed
15.
go back to reference Deng X, Tang CY, Zhang J, Zhu L, Xie ZC, Gong HH, et al. The cortical thickness correlates of clinical manifestations in the mid-stage sporadic Parkinson's disease. Neurosci Lett. 2016;633:279–89.CrossRefPubMed Deng X, Tang CY, Zhang J, Zhu L, Xie ZC, Gong HH, et al. The cortical thickness correlates of clinical manifestations in the mid-stage sporadic Parkinson's disease. Neurosci Lett. 2016;633:279–89.CrossRefPubMed
16.
go back to reference Huang P, Lou Y, Xuan M, Gu Q, Guan X, Xu X, et al. Cortical abnormalities in Parkinson’s disease patients and relationship to depression: a surface-based morphometry study. Psychiatry Res. 2016;250:24–8.CrossRefPubMed Huang P, Lou Y, Xuan M, Gu Q, Guan X, Xu X, et al. Cortical abnormalities in Parkinson’s disease patients and relationship to depression: a surface-based morphometry study. Psychiatry Res. 2016;250:24–8.CrossRefPubMed
17.
go back to reference Mayberg HS, Starkstein SE, Sadzot B, Preziosi T, Andrezejewski PL, Dannals RF, et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol. 1990;28:57–64.CrossRefPubMed Mayberg HS, Starkstein SE, Sadzot B, Preziosi T, Andrezejewski PL, Dannals RF, et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol. 1990;28:57–64.CrossRefPubMed
18.
go back to reference Mentis MJ, McIntosh AR, Perrine K, Dhawan V, Berlin B, Feigin A, et al. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson’s disease. Am J Psychiatry. 2002;159:746–54.CrossRefPubMed Mentis MJ, McIntosh AR, Perrine K, Dhawan V, Berlin B, Feigin A, et al. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson’s disease. Am J Psychiatry. 2002;159:746–54.CrossRefPubMed
19.
go back to reference Luo C, Chen Q, Song W, Chen K, Guo X, Yang J, et al. Resting-state fMRI study on drug-naive patients with Parkinson’s disease and with depression. J Neurol Neurosurg Psychiatry. 2014;85:675–83.CrossRefPubMed Luo C, Chen Q, Song W, Chen K, Guo X, Yang J, et al. Resting-state fMRI study on drug-naive patients with Parkinson’s disease and with depression. J Neurol Neurosurg Psychiatry. 2014;85:675–83.CrossRefPubMed
20.
go back to reference Schultz W, Tremblay L, Hollerman JR. Reward processing in primate orbitofrontal cortex and basal ganglia. Cereb Cortex. 2000;10(3):272–83.CrossRefPubMed Schultz W, Tremblay L, Hollerman JR. Reward processing in primate orbitofrontal cortex and basal ganglia. Cereb Cortex. 2000;10(3):272–83.CrossRefPubMed
21.
go back to reference Amemori K, Graybiel AM. Localized microstimulation of primate pregenual cingulate cortex induces negative decision-making. Nat Neurosci. 2012;15(5):776–85.CrossRefPubMedPubMedCentral Amemori K, Graybiel AM. Localized microstimulation of primate pregenual cingulate cortex induces negative decision-making. Nat Neurosci. 2012;15(5):776–85.CrossRefPubMedPubMedCentral
22.
go back to reference Wen X, Wu X, Liu J, Li K, Yao L. Abnormal baseline brain activity in non-depressed Parkinson's disease and depressed Parkinson’s disease: a resting-state functional magnetic resonance imaging study. PLoS One. 2013;8:e63691.CrossRefPubMedPubMedCentral Wen X, Wu X, Liu J, Li K, Yao L. Abnormal baseline brain activity in non-depressed Parkinson's disease and depressed Parkinson’s disease: a resting-state functional magnetic resonance imaging study. PLoS One. 2013;8:e63691.CrossRefPubMedPubMedCentral
23.
go back to reference Matsui H, Nishinaka K, Oda M, Komatsu K, Kubori T, Udaka F. Minor depression and brain perfusion images in Parkinson’s disease. Mov Disord. 2006;21(8):1169–74.CrossRefPubMed Matsui H, Nishinaka K, Oda M, Komatsu K, Kubori T, Udaka F. Minor depression and brain perfusion images in Parkinson’s disease. Mov Disord. 2006;21(8):1169–74.CrossRefPubMed
24.
go back to reference Luo C, Song W, Chen Q, Yang J, Gong Q, Shang HF. Cortical thinning in drug-naive Parkinson’s disease patients with depression. J Neurol. 2016;263(10):2114–9.CrossRefPubMed Luo C, Song W, Chen Q, Yang J, Gong Q, Shang HF. Cortical thinning in drug-naive Parkinson’s disease patients with depression. J Neurol. 2016;263(10):2114–9.CrossRefPubMed
25.
go back to reference Reijnders JS, Scholtissen B, Weber WE, Aalten P, Verhey FR, Leentjens AF. Neuroanatomical correlates of apathy in Parkinson’s disease: a magnetic resonance imaging study using voxel-based morphometry. Mov Disord. 2010;25:2318–25.CrossRefPubMed Reijnders JS, Scholtissen B, Weber WE, Aalten P, Verhey FR, Leentjens AF. Neuroanatomical correlates of apathy in Parkinson’s disease: a magnetic resonance imaging study using voxel-based morphometry. Mov Disord. 2010;25:2318–25.CrossRefPubMed
26.
go back to reference Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry. 1999;156:675–82.PubMed Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry. 1999;156:675–82.PubMed
27.
go back to reference Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45:651–60.CrossRefPubMed Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45:651–60.CrossRefPubMed
28.
go back to reference Cardoso EF, Maia FM, Fregni F, Myczkowski ML, Melo LM, Sato JR, et al. Depression in Parkinson’s disease: convergence from voxel-based morphometry and functional magnetic resonance imaging in the limbic thalamus. NeuroImage. 2009;47:467–72.CrossRefPubMed Cardoso EF, Maia FM, Fregni F, Myczkowski ML, Melo LM, Sato JR, et al. Depression in Parkinson’s disease: convergence from voxel-based morphometry and functional magnetic resonance imaging in the limbic thalamus. NeuroImage. 2009;47:467–72.CrossRefPubMed
29.
go back to reference Li W, Liu J, Skidmore F, Liu Y, Tian J, Li K. White matter microstructure changes in the thalamus in Parkinson disease with depression: a diffusion tensor MR imaging study. AJNR Am J Neuroradiol. 2010;31:1861–6.CrossRefPubMed Li W, Liu J, Skidmore F, Liu Y, Tian J, Li K. White matter microstructure changes in the thalamus in Parkinson disease with depression: a diffusion tensor MR imaging study. AJNR Am J Neuroradiol. 2010;31:1861–6.CrossRefPubMed
30.
go back to reference Sheng K, Fang W, Su M, Li R, Zou D, Han Y, et al. Altered spontaneous brain activity in patients with Parkinson’s disease accompanied by depressive symptoms, as revealed by regional homogeneity and functional connectivity in the prefrontal-limbic system. PLoS One. 2014;9:e84705.CrossRefPubMedPubMedCentral Sheng K, Fang W, Su M, Li R, Zou D, Han Y, et al. Altered spontaneous brain activity in patients with Parkinson’s disease accompanied by depressive symptoms, as revealed by regional homogeneity and functional connectivity in the prefrontal-limbic system. PLoS One. 2014;9:e84705.CrossRefPubMedPubMedCentral
31.
go back to reference Hu X, Song X, Li E, Liu J, Yuan Y, Liu W, et al. Altered resting-state brain activity and connectivity in depressed Parkinson’s disease. PLoS One. 2015;10(7):e0131133.CrossRefPubMedPubMedCentral Hu X, Song X, Li E, Liu J, Yuan Y, Liu W, et al. Altered resting-state brain activity and connectivity in depressed Parkinson’s disease. PLoS One. 2015;10(7):e0131133.CrossRefPubMedPubMedCentral
32.
go back to reference Lou Y, Huang P, Li D, Cen Z, Wang B, Gao J, et al. Altered brain network centrality in depressed Parkinson’s disease patients. Mov Disord. 2015;30(13):1777–84.CrossRefPubMed Lou Y, Huang P, Li D, Cen Z, Wang B, Gao J, et al. Altered brain network centrality in depressed Parkinson’s disease patients. Mov Disord. 2015;30(13):1777–84.CrossRefPubMed
33.
go back to reference Huang P, Xu X, Gu Q, Xuan M, Yu X, Luo W, et al. Disrupted white matter integrity in depressed versus non-depressed Parkinson’s disease patients: a tract-based spatial statistics study. J Neurol Sci. 2014;346(1–2):145–8.CrossRefPubMed Huang P, Xu X, Gu Q, Xuan M, Yu X, Luo W, et al. Disrupted white matter integrity in depressed versus non-depressed Parkinson’s disease patients: a tract-based spatial statistics study. J Neurol Sci. 2014;346(1–2):145–8.CrossRefPubMed
34.
go back to reference Le Jeune F, Drapier D, Bourguignon A, Péron J, Mesbah H, Drapier S, et al. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology. 2009;73:1746–51.CrossRefPubMed Le Jeune F, Drapier D, Bourguignon A, Péron J, Mesbah H, Drapier S, et al. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology. 2009;73:1746–51.CrossRefPubMed
35.
go back to reference Robert G, Le Jeune F, Lozachmeur C, Drapier S, Dondaine T, Péron J, et al. Apathy in patients with Parkinson disease without dementia or depression: a PET study. Neurology. 2012;79:1155–60.CrossRefPubMed Robert G, Le Jeune F, Lozachmeur C, Drapier S, Dondaine T, Péron J, et al. Apathy in patients with Parkinson disease without dementia or depression: a PET study. Neurology. 2012;79:1155–60.CrossRefPubMed
36.
go back to reference • Carriere N, Besson P, Dujardin K, Duhamel A, Defebvre L, Delmaire C, et al. Apathy in Parkinson’s disease is associated with nucleus accumbens atrophy: a magnetic resonance imaging shape analysis. Mov Disord. 2014;29:897–903. MRI study underlying morphological abnormalities of the ventral striatum (a key area for motivational processes) in apathetic PD patients. CrossRefPubMed • Carriere N, Besson P, Dujardin K, Duhamel A, Defebvre L, Delmaire C, et al. Apathy in Parkinson’s disease is associated with nucleus accumbens atrophy: a magnetic resonance imaging shape analysis. Mov Disord. 2014;29:897–903. MRI study underlying morphological abnormalities of the ventral striatum (a key area for motivational processes) in apathetic PD patients. CrossRefPubMed
37.
go back to reference Robert GH, Le Jeune F, Lozachmeur C, Drapier S, Dondaine T, Péron J, et al. Preoperative factors of apathy in subthalamic stimulated Parkinson disease: a PET study. Neurology. 2014;83:1620–6.CrossRefPubMed Robert GH, Le Jeune F, Lozachmeur C, Drapier S, Dondaine T, Péron J, et al. Preoperative factors of apathy in subthalamic stimulated Parkinson disease: a PET study. Neurology. 2014;83:1620–6.CrossRefPubMed
38.
go back to reference Gesquière-Dando A, Guedj E, Loundou A, Carron R, Witjas T, Fluchère F, et al. A preoperative metabolic marker of parkinsonian apathy following subthalamic nucleus stimulation. Mov Disord. 2015;30(13):1767–76.CrossRefPubMed Gesquière-Dando A, Guedj E, Loundou A, Carron R, Witjas T, Fluchère F, et al. A preoperative metabolic marker of parkinsonian apathy following subthalamic nucleus stimulation. Mov Disord. 2015;30(13):1767–76.CrossRefPubMed
39.
go back to reference Baggio HC, Segura B, Garrido-Millan JL, Marti MJ, Compta Y, Valldeoriola F, et al. Resting-state frontostriatal functional connectivity in Parkinson’s disease-related apathy. Mov Disord. 2015;30:671–9.CrossRefPubMed Baggio HC, Segura B, Garrido-Millan JL, Marti MJ, Compta Y, Valldeoriola F, et al. Resting-state frontostriatal functional connectivity in Parkinson’s disease-related apathy. Mov Disord. 2015;30:671–9.CrossRefPubMed
40.
go back to reference Lawrence AD, Goerendt IK, Brooks DJ. Apathy blunts neural response to money in Parkinson's disease. Soc Neurosci. 2011;6(5–6):653–62. 122CrossRefPubMed Lawrence AD, Goerendt IK, Brooks DJ. Apathy blunts neural response to money in Parkinson's disease. Soc Neurosci. 2011;6(5–6):653–62. 122CrossRefPubMed
41.
go back to reference Levita L, Hoskin R, Champi S. Avoidance of harm and anxiety: a role for the nucleus accumbens. NeuroImage. 2012;62(1):189–98.CrossRefPubMed Levita L, Hoskin R, Champi S. Avoidance of harm and anxiety: a role for the nucleus accumbens. NeuroImage. 2012;62(1):189–98.CrossRefPubMed
42.
go back to reference •• Thobois S, Ardouin C, Lhommee E, Klinger H, Lagrange C, Xie J, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: predictors and underlying mesolimbic denervation. Brain. 2010;133:1111–27. Large clinical and PET study demonstrating different profile of mesolimbic dopaminergic denervation responsible for different risk of developping apathy after STN stimulation in PD. CrossRefPubMed •• Thobois S, Ardouin C, Lhommee E, Klinger H, Lagrange C, Xie J, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: predictors and underlying mesolimbic denervation. Brain. 2010;133:1111–27. Large clinical and PET study demonstrating different profile of mesolimbic dopaminergic denervation responsible for different risk of developping apathy after STN stimulation in PD. CrossRefPubMed
43.
go back to reference Broussolle E, Dentresangle C, Landais P, Garcia-Larrea L, Pollak P, Croisile B, et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci. 1999;166:141–51.CrossRefPubMed Broussolle E, Dentresangle C, Landais P, Garcia-Larrea L, Pollak P, Croisile B, et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci. 1999;166:141–51.CrossRefPubMed
44.
go back to reference Koerts J, Leenders KL, Koning M, Portman AT, van Beilen M. Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson’s disease. Eur J Neurosci. 2007;25:3132–6.CrossRefPubMed Koerts J, Leenders KL, Koning M, Portman AT, van Beilen M. Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson’s disease. Eur J Neurosci. 2007;25:3132–6.CrossRefPubMed
45.
go back to reference Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med. 2005;46:227–32.PubMed Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med. 2005;46:227–32.PubMed
46.
go back to reference Rektorova I, Srovnalova H, Kubikova R, Prasek J. Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson’s disease. Mov Disord. 2008;23(11):1580–7.CrossRefPubMed Rektorova I, Srovnalova H, Kubikova R, Prasek J. Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson’s disease. Mov Disord. 2008;23(11):1580–7.CrossRefPubMed
47.
go back to reference Hesse S, Meyer PM, Strecker K, Barthel H, Wegner F, Oehlwein C, et al. Monoamine transporter availability in Parkinson’s disease patients with or without depression. Eur J Nucl Med Mol Imaging. 2009;36(3):428–35.CrossRefPubMed Hesse S, Meyer PM, Strecker K, Barthel H, Wegner F, Oehlwein C, et al. Monoamine transporter availability in Parkinson’s disease patients with or without depression. Eur J Nucl Med Mol Imaging. 2009;36(3):428–35.CrossRefPubMed
48.
go back to reference Erro R, Pappata S, Amboni M, Vicidomini C, Longo K, Santangelo G, et al. Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson’s disease patients. Parkinsonism Relat Disord. 2012;18:1034–8.CrossRefPubMed Erro R, Pappata S, Amboni M, Vicidomini C, Longo K, Santangelo G, et al. Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson’s disease patients. Parkinsonism Relat Disord. 2012;18:1034–8.CrossRefPubMed
49.
go back to reference •• Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128:1314–22. First study demonstrating a link between apathy, depression and anxiety and dopaminergic lesions within limbic network. CrossRefPubMed •• Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128:1314–22. First study demonstrating a link between apathy, depression and anxiety and dopaminergic lesions within limbic network. CrossRefPubMed
50.
go back to reference Felicio AC, Moriyama TS, Godeiro-Junior C, Shih MC, Hoexter MQ, Borges V, et al. Higher dopamine transporter density in Parkinson’s disease patients with depression. Psychopharmacology. 2010;211:27–31.CrossRefPubMed Felicio AC, Moriyama TS, Godeiro-Junior C, Shih MC, Hoexter MQ, Borges V, et al. Higher dopamine transporter density in Parkinson’s disease patients with depression. Psychopharmacology. 2010;211:27–31.CrossRefPubMed
51.
go back to reference Moriyama TS, Felicio AC, Chagas MH, Tardelli VS, Ferraz HB, Tumas V, et al. Increased dopamine transporter density in Parkinson’s disease patients with social anxiety disorder. J Neurol Sci. 2011;310:53–7.CrossRefPubMed Moriyama TS, Felicio AC, Chagas MH, Tardelli VS, Ferraz HB, Tumas V, et al. Increased dopamine transporter density in Parkinson’s disease patients with social anxiety disorder. J Neurol Sci. 2011;310:53–7.CrossRefPubMed
52.
go back to reference Ceravolo R, Frosini D, Poletti M, Kiferle L, Pagni C, Mazzucchi S, et al. Mild affective symptoms in de novo Parkinson’s disease patients: relationship with dopaminergic dysfunction. Eur J Neurol. 2013;20:480–5.CrossRefPubMed Ceravolo R, Frosini D, Poletti M, Kiferle L, Pagni C, Mazzucchi S, et al. Mild affective symptoms in de novo Parkinson’s disease patients: relationship with dopaminergic dysfunction. Eur J Neurol. 2013;20:480–5.CrossRefPubMed
53.
go back to reference Boileau I, Guttman M, Rusjan P, Adams JR, Houle S, Tong J, et al. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson’s disease. Brain. 2009;132:1366–75.CrossRefPubMed Boileau I, Guttman M, Rusjan P, Adams JR, Houle S, Tong J, et al. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson’s disease. Brain. 2009;132:1366–75.CrossRefPubMed
54.
go back to reference Rektorova I, Rektor I, Bares M, Dostál V, Ehler E, Fanfrdlová Z, et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol. 2003;10:399–406.CrossRefPubMed Rektorova I, Rektor I, Bares M, Dostál V, Ehler E, Fanfrdlová Z, et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol. 2003;10:399–406.CrossRefPubMed
55.
go back to reference •• Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573–80. Seminal paper demonstrating the response of depression to dopamine agonist in PD patients. CrossRefPubMed •• Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573–80. Seminal paper demonstrating the response of depression to dopamine agonist in PD patients. CrossRefPubMed
56.
go back to reference Ray Chaudhuri K, Martinez-Martin P, Antonini A, Antonini A, Brown RG, Friedman JH, et al. Rotigotine and specific non-motor symptoms of Parkinson’s disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013;19:660–5.CrossRefPubMed Ray Chaudhuri K, Martinez-Martin P, Antonini A, Antonini A, Brown RG, Friedman JH, et al. Rotigotine and specific non-motor symptoms of Parkinson’s disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013;19:660–5.CrossRefPubMed
57.
go back to reference Antonini A, Bauer L, Dohin E, Oertel WH, Rascol O, Reichmann H, et al. Effects of rotigotine transdermal patch in patients with Parkinson’s disease presenting with non-motor symptoms—results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol. 2015;22:1400–7.CrossRefPubMed Antonini A, Bauer L, Dohin E, Oertel WH, Rascol O, Reichmann H, et al. Effects of rotigotine transdermal patch in patients with Parkinson’s disease presenting with non-motor symptoms—results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol. 2015;22:1400–7.CrossRefPubMed
58.
go back to reference Troeung L, Egan SJ, Gasson N. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson’s disease. PLoS One. 2013;8:e79510.CrossRefPubMedPubMedCentral Troeung L, Egan SJ, Gasson N. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson’s disease. PLoS One. 2013;8:e79510.CrossRefPubMedPubMedCentral
59.
go back to reference Chung SJ, Asgharnejad M, Bauer L, Ramirez F, Jeon B. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson’s disease. Expert Opin Pharmacother. 2016;17(11):1453–61.CrossRefPubMed Chung SJ, Asgharnejad M, Bauer L, Ramirez F, Jeon B. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson’s disease. Expert Opin Pharmacother. 2016;17(11):1453–61.CrossRefPubMed
60.
go back to reference Leentjens AF. The role of dopamine agonists in the treatment of depression in patients with Parkinson’s disease: a systematic review. Drugs. 2011;71(3):273–86.CrossRefPubMed Leentjens AF. The role of dopamine agonists in the treatment of depression in patients with Parkinson’s disease: a systematic review. Drugs. 2011;71(3):273–86.CrossRefPubMed
61.
go back to reference • Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58–63. First description of dopamine withdrawal syndrome after dopamine agonists arrest in PD. CrossRefPubMed • Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58–63. First description of dopamine withdrawal syndrome after dopamine agonists arrest in PD. CrossRefPubMed
62.
go back to reference Qamhawi Z, Towey D, Shah B, Pagano G, Seibyl J, Marek K, et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson’s disease. Brain. 2015;138:2964–297.CrossRefPubMed Qamhawi Z, Towey D, Shah B, Pagano G, Seibyl J, Marek K, et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson’s disease. Brain. 2015;138:2964–297.CrossRefPubMed
63.
go back to reference •• Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P, et al. Elevated serotonin transporter binding in depressed patients with Parkinson’s disease: a preliminary PET study with [11C]DASB. Mov Disord. 2008;23:1776–80. This PET study highlighted the role of serotonergic lesions in depression in PD. CrossRefPubMed •• Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P, et al. Elevated serotonin transporter binding in depressed patients with Parkinson’s disease: a preliminary PET study with [11C]DASB. Mov Disord. 2008;23:1776–80. This PET study highlighted the role of serotonergic lesions in depression in PD. CrossRefPubMed
64.
go back to reference Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology. 2010;75:1920–7.CrossRefPubMed Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology. 2010;75:1920–7.CrossRefPubMed
65.
go back to reference Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, McCluskey T, et al. Brain serotonin transporter binding in non-depressed patients with Parkinson’s disease. Eur J Neurol. 2007;14(5):523–8.CrossRefPubMed Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, McCluskey T, et al. Brain serotonin transporter binding in non-depressed patients with Parkinson’s disease. Eur J Neurol. 2007;14(5):523–8.CrossRefPubMed
66.
go back to reference Ballanger B, Klinger H, Eche J, Lerond J, Vallet AE, Le Bars D, et al. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. Mov Disord. 2012;27:84–9.CrossRefPubMed Ballanger B, Klinger H, Eche J, Lerond J, Vallet AE, Le Bars D, et al. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. Mov Disord. 2012;27:84–9.CrossRefPubMed
67.
go back to reference Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Oertel WH, et al. Serotonin neuron loss and nonmotor symptoms continue in Parkinson’s patients treated with dopamine grafts. Sci Transl Med. 2012;4:128ra141.CrossRef Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Oertel WH, et al. Serotonin neuron loss and nonmotor symptoms continue in Parkinson’s patients treated with dopamine grafts. Sci Transl Med. 2012;4:128ra141.CrossRef
68.
go back to reference •• Maillet A, Krack P, Lhommée E, Météreau E, Klinger H, Favre E, et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain. 2016;139(Pt 9):2486–502. First study demonstrating in de novo PD patients a major relationship between serotonergic lesions, apathy, depression and anxiety, while the role of dopaminergic lesions appears less prominent. CrossRefPubMed •• Maillet A, Krack P, Lhommée E, Météreau E, Klinger H, Favre E, et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain. 2016;139(Pt 9):2486–502. First study demonstrating in de novo PD patients a major relationship between serotonergic lesions, apathy, depression and anxiety, while the role of dopaminergic lesions appears less prominent. CrossRefPubMed
69.
go back to reference Becker T, Becker G, Seufert J, Hofmann E, Lange KW, Naumann M, et al. Parkinson’s disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography. J Neurol Neurosurg Psychiatry. 1997;63(5):590–6.CrossRefPubMedPubMedCentral Becker T, Becker G, Seufert J, Hofmann E, Lange KW, Naumann M, et al. Parkinson’s disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography. J Neurol Neurosurg Psychiatry. 1997;63(5):590–6.CrossRefPubMedPubMedCentral
70.
go back to reference Berg D, Supprian T, Hofmann E, Zeiler B, Jäger A, Lange KW, et al. Depression in Parkinson’s disease: brainstem midline alteration on transcranial sonography and magnetic resonance imaging. J Neurol. 1999;246(12):1186–93.CrossRefPubMed Berg D, Supprian T, Hofmann E, Zeiler B, Jäger A, Lange KW, et al. Depression in Parkinson’s disease: brainstem midline alteration on transcranial sonography and magnetic resonance imaging. J Neurol. 1999;246(12):1186–93.CrossRefPubMed
71.
go back to reference Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease. Mov Disord. 1997;12(5):756–9.CrossRefPubMed Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease. Mov Disord. 1997;12(5):756–9.CrossRefPubMed
72.
go back to reference Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology. 2000;55:1216–8.CrossRefPubMed Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology. 2000;55:1216–8.CrossRefPubMed
73.
go back to reference Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G. Tolerability of paroxetine in Parkinson’s disease: a prospective study. Mov Disord. 2000;15(5):986–9.CrossRefPubMed Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G. Tolerability of paroxetine in Parkinson’s disease: a prospective study. Mov Disord. 2000;15(5):986–9.CrossRefPubMed
74.
go back to reference Antonini A, Tesei S, Zecchinelli A, et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. Mov Disord. 2006;21:1119–22.CrossRefPubMed Antonini A, Tesei S, Zecchinelli A, et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. Mov Disord. 2006;21:1119–22.CrossRefPubMed
75.
go back to reference Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253:601–7.CrossRefPubMed Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253:601–7.CrossRefPubMed
76.
go back to reference Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008;23:850–7.CrossRefPubMed Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008;23:850–7.CrossRefPubMed
77.
go back to reference Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78:1229–36.CrossRefPubMedPubMedCentral Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78:1229–36.CrossRefPubMedPubMedCentral
78.
go back to reference Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75:448–55.CrossRefPubMedPubMedCentral Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75:448–55.CrossRefPubMedPubMedCentral
79.
go back to reference • Bohnen NI, Kaufer DI, Hendrickson R, Constantine GM, Mathis CA, Moore RY. Cortical cholinergic denervation is associated with depressive symptoms in Parkinson’s disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry. 2007;78(6):641–3. First study linking depression and cholinergic lesions in PD. CrossRefPubMedPubMedCentral • Bohnen NI, Kaufer DI, Hendrickson R, Constantine GM, Mathis CA, Moore RY. Cortical cholinergic denervation is associated with depressive symptoms in Parkinson’s disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry. 2007;78(6):641–3. First study linking depression and cholinergic lesions in PD. CrossRefPubMedPubMedCentral
80.
go back to reference Oh YS, Kim JS, Lee PH. Effect of Rivastigmine on behavioral and psychiatric symptoms of Parkinson’s disease dementia. J Mov Disord. 2015;8(2):98–102.CrossRefPubMedPubMedCentral Oh YS, Kim JS, Lee PH. Effect of Rivastigmine on behavioral and psychiatric symptoms of Parkinson’s disease dementia. J Mov Disord. 2015;8(2):98–102.CrossRefPubMedPubMedCentral
81.
go back to reference Santangelo G, Vitale C, Picillo M, Cuoco S, Moccia M, Pezzella D, et al. Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson’s disease patients. Parkinsonism Relat Disord. 2015;21:489–93.CrossRefPubMed Santangelo G, Vitale C, Picillo M, Cuoco S, Moccia M, Pezzella D, et al. Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson’s disease patients. Parkinsonism Relat Disord. 2015;21:489–93.CrossRefPubMed
82.
go back to reference Czernecki V, Schupbach M, Yaici S, Lévy R, Bardinet E, Yelnik J, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord. 2008;23:964–9.CrossRefPubMed Czernecki V, Schupbach M, Yaici S, Lévy R, Bardinet E, Yelnik J, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord. 2008;23:964–9.CrossRefPubMed
83.
go back to reference Thobois S, Lhommee E, Klinger H, Ardouin C, Schmitt E, Bichon A, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain. 2013;136:1568–77.CrossRefPubMed Thobois S, Lhommee E, Klinger H, Ardouin C, Schmitt E, Bichon A, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain. 2013;136:1568–77.CrossRefPubMed
84.
go back to reference Chung SJ, Lee JJ, Ham JH, Lee PH, Sohn YH. Apathy and striatal dopamine defects in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord. 2016;23:62–5.CrossRefPubMed Chung SJ, Lee JJ, Ham JH, Lee PH, Sohn YH. Apathy and striatal dopamine defects in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord. 2016;23:62–5.CrossRefPubMed
85.
go back to reference • Sgambato-Faure V, Tremblay L. Dopamine and serotonin modulation of motor and non-motor functions of the non-human primate striato-pallidal circuits in normal and pathological states. J Neural Transm (Vienna). 2017. doi:10.1007/s00702-017-1693-z. Excellent review on the complex role of serotonergic and dopaminergic system on motor and non motor manifestations. • Sgambato-Faure V, Tremblay L. Dopamine and serotonin modulation of motor and non-motor functions of the non-human primate striato-pallidal circuits in normal and pathological states. J Neural Transm (Vienna). 2017. doi:10.​1007/​s00702-017-1693-z. Excellent review on the complex role of serotonergic and dopaminergic system on motor and non motor manifestations.
86.
go back to reference • Devos D, Moreau C, Maltete D, Lefaucheur R, Kreisler A, Eusebio A, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry. 2014;85:668–74. First study demonstrating an impact of anticholinesterase drug on apathy in PD. CrossRefPubMed • Devos D, Moreau C, Maltete D, Lefaucheur R, Kreisler A, Eusebio A, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry. 2014;85:668–74. First study demonstrating an impact of anticholinesterase drug on apathy in PD. CrossRefPubMed
Metadata
Title
Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson’s Disease: Implication for Treatment
Authors
Stephane Thobois
Stephane Prange
Véronique Sgambato-Faure
Léon Tremblay
Emmanuel Broussolle
Publication date
01-10-2017
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 10/2017
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-017-0788-0

Other articles of this Issue 10/2017

Current Neurology and Neuroscience Reports 10/2017 Go to the issue

Stroke (H Diener, Section Editor)

DVT Prevention in Stroke

Nerve and Muscle (L H Weimer, Section Editor)

Sensory Neuronopathies